Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;114(1):30-37.
doi: 10.1177/0141076820972669. Epub 2020 Dec 3.

Recent advances in treatment of haemodialysis

Affiliations
Review

Recent advances in treatment of haemodialysis

James O Burton et al. J R Soc Med. 2021 Jan.

Abstract

Haemodialysis remains the most widely used treatment for patients with end-stage renal disease. Despite the progress that has occurred in the treatment of end-stage renal disease over the last six decades, there has been a failure to translate this into the desired clinical benefits, with morbidity and mortality rates among patients on haemodialysis remaining unacceptably high. Recently, however, there have been expectations that the significant advances that took place over the last few years may result in improved outcomes. New medications for the treatment of anaemia and secondary hyperparathyroidism, as well as novel trends in the areas of iron therapy, diabetes management and physical exercise are among the most important advances which, taken together, are changing the standards of care for patients on haemodialysis. The latest advances, of relevance not only to specialists in Renal Medicine but also to general practitioners caring for these patients, are reviewed in this collaborative paper.

Keywords: Chronic renal failure; clinical; diabetes; dialysis; endocrinology; haematology (incl blood transfusion); physiotherapy; rehabilitation medicine; renal medicine.

PubMed Disclaimer

References

    1. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Executive Summary. See www.usrds.org/2019/view/USRDS_2019_ES_final.pdf (last checked 25 October 2020).
    1. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 2011; 124: 2903–2908. - PubMed
    1. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162–168. - PubMed
    1. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380: 447–458. - PubMed
    1. Pyart R, Gilg J, Williams A. Chapter 7 Haemoglobin ferritin and erythropoietin in adult dialysis patients in 2016 UKRR 20th annual report 2017. Nephron 2018; 139: 1–372. - PubMed